Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
https://doi.org/10.14341/2072-0351-3597
Abstract
Body weight (BW) excess is a characteristic problem for type 2 diabetes mellitus (T2DM) both as its pathogenetic feature and as a side effect of blood glucose lowering therapy. In the latter case reduction of glycosuria and frequent hypoglycemic events are primarily blamed for BW gain, but additional factors like direct effect of insulin on lipogenesis and influence of its supraphysiologic levels on regulation of appetite via CNS structures are also under discussion.Advances of the last years have brought new hope due to introduction of drug classes that do not affect BW. However, fraction of patients dependent on exogenous insulin shows stable trend for growth. Deterioration of beta-cell secretory capacity makes insulin an ultimately indispensable tool in the foreseeable future. As so, insulin therapy modalities with minimal impact on BW are preferable. In this regard human insulin analogues of both rapid and prolonged action have certain advantages.Current article addresses influence of pre-mixed insulin preparation NovoMix 30 (Novo Nordisk, Denmark) on BW. A summary of several studies of substantial duration (up to 3 years) suggests a neutral effect on BW in various categories of T2DM patients (including obese and elder patients).Therapy with pre-mixed preparations is an adequately safe and effective T2DM treatment modality and is advantageous for patients in whom BW gain is particularly unfavorable.
References
1. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effect of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. 2001 Dec;3(6):410–416.
2. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group Diabetes Care. 1988 Jul–Aug;11(7):567–573.
3. Strachan MW, Ewing FM, Frier BM, Harper A, Deary IJ. Food craving during acute hypoglycaemia in adults with type 1 dia- betes. Physiol Behav. 2004 Feb;80(5):675–682.
4. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep. 2001 Apr;2(4):282–286.
5. Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes spectrum. 2007;20(3):159–165. DOI: 10.2337/di- aspect.20.3.159
6. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000 Apr 6;404(6778):661–671.
7. Ryan M, Livingstone MB, Ducluzeau PH, Sallé A, Genaitay M, Ritz P. Is a failure to recognize an increase in food intake a key to understanding insulin-induced weight gain? Diabetes Care. 2008 Mar;31(3):448–450.
8. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care. 2001 Oct;24(10):1849–1850.
9. American Diabetes Association. Shaban J, Hansen JB, Wenying Y. NovoMix 30 (BIAsp 30) Improves Glycemic Control in Type 2 Diabetes: Results from the IMPROVE Study. Diabetes Care. 2008 Jan;31 Suppl 1:S12–54. DOI: 10.2337/dc08-S012.
10. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM; PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008 Mar;10(3):212–222. DOI: 10.1111/j.1463–1326.2007.00826.x.
11. Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007 Dec;23(12):3209–3214.
12. Valency P. Biphasic insulin aspart 30/70 (BiAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes. 2009 Jun 3;2:61–71.
13. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M. Starting Insulin Therapy in Type 2 Diabetes: Twice-Daily Biphasic Insulin Aspart 30 Plus Metformin versus Once-Daily Insulin Glargine Plus Glimepiride. Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):527–532.
14. Ligthelm RJ. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Prim Care Diabetes. 2009 May;3(2):97–102. DOI: 10.1016/j.pcd.2009.01.003.
15. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest. 2009 Jan;32(1):23–27.
16. Arai K, Hirao K, Yamauchi M, Takagi H, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Influence of BMI, Age and Duration of Diabetes Mellitus on Glycaemic Control with Twice-Daily Injections of Biphasic Insulin Aspart 30 versus Multiple Daily Injections of Insulin Aspart (JDDM 18) Retrospective Reanalysis of a 6-Month, Randomized, Open-Label, Multicentre Trial in Japan. Clin Drug Investig. 2010;30(1):35–40.DOI: 10.2165/11530920-000000000-00000.
17. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):148–152. DOI: 10.1097/ MED.0b013e3283444ba0.
18. Tilling LM, Darawill K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications. 2006 May–Jun;20(3):158–162.
19. Jang HC, Lee SR, Vaz JA. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMix study. Diabetes Obes Metab. 2009 Jan;11(1):20–26. DOI: 10.1111/j.1463- 1326.2008.00891.x.
20. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams- Huet B, Raskin P. Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2. Diabetes Care. 2009 Oct;32(10):1789–1795. DOI: 10.2337/dc09-0653.
21. Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 2011 Feb;65(2):165–171. DOI: 10.1111/j.1742-1241.2010.02513.x.
Review
For citations:
Surkova E.V. Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30. Diabetes mellitus. 2013;16(1):52-56. (In Russ.) https://doi.org/10.14341/2072-0351-3597
Views:
1254
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
